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Abstract 
Positron emission tompography with radiolabeled (with 11C- or 18F-) choline has received 
much attention, particularly in Europe and Japan, over the past several years.  While moni-
toring cellular membrane lipogenesis with radiolabeled choline is nonspecific for cancer, the 
malignancy-induced increased demand for cellular membrane synthesis can be a useful feature 
for imaging-based diagnosis and treatment evaluation.   Many choline PET(/CT) studies have 
focused on prostate cancer given that 18F-flurodeoxyglucose appears to be primarily useful in 
progressive metastatic disease and is overall limited in the initial staging of disease or for 
evaluation of men with biochemical recurrence.  The current evidence suggests that choline 
PET(/CT), particularly the 18F- label, may become routinely available, initially in many Eu-
ropean countries, for the clinical imaging evaluation of men with prostate cancer. 
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Prostate cancer is a growing public health prob-
lem.    Accurate  imaging  evaluation  of  this  clinically 
heterogeneous  disease  can  pave  the  way  for  more 
optimal care of men with prostate cancer which may 
include a spectrum from active surveillance to active 
treatment.    Evidence  derived  from  imaging  studies 
over the past many years suggest that use of different 
imaging modalities may need to be aligned with the 
clinical phase of the disease.   
There has been a plethora of research activity in 
recent  years  toward  development  of  multimodality 
imaging  techniques  that  can  provide  non-invasive 
interrogation of the complex biology of prostate can-
cer.    These  efforts  have  been  fueled  by  continuous 
advances  in  our  fundamental  understanding  of  the 
pathophysiology  of  prostate  cancer  and  the  many 
currently unmet clinical needs that have been partly 
brought forward into spotlight because of new ther-
apeutic approaches that are becoming rapidly availa-
ble for castration-resistant prostate cancer.  In order to 
be able to compare the available therapeutic options, 
there  is  an  urgent  need  for  objective  assessment  of 
disease  status  to  guide  appropriate  treatment  with 
anticipated  higher  success  rate  and  to  be  able  to 
evaluate  response  to  treatment  accurately.    This 
strategy also needs to be aligned with the paradigm 
shift in cancer therapy that calls for continuation of 
therapy as long as the disease manifestations are con-
trolled and/or new manifestations are prevented or 
delayed (1). 
Positron emission tomography (PET) combined 
with  computed  tomography  (CT)  or  with  magnetic 
resonance imaging (MRI) can provide powerful hy-
brid anatomic and functional imaging evaluation of 
prostate cancer.  CT provides means for attenuation 
correction of PET emission data and for precise local-
Ivyspring  




ization of findings on PET.  Multiparametric MRI in-
cluding techniques such as diffusion-weighted imag-
ing (DWI), dynamic contrast enhancement (DCE) and 
magnetic  resonance  spectrospcopy  (MRS)  are  now 
being  actively  investigated  in  prostate  cancer  (2).  
Imaging  evaluation  of  prostate  cancer  may  in  fact 
develop into an appropriate indication for the recently 
developed integarted PET/MRI imaging systems (3).   
The power of PET is its ability to provide bio-
distribution  map  of  the  biologically  relevant  radio-
tracers.  In case of prostate cancer, many candidate 
radiotracers have been designed and evaluated in the 
pre-clinical  and  pilot  clinical  arenas.    These  tracers 
include  those  that  interrogate  glucose  metabolism, 
fatty  acid  metabolism,  amino  acid  metabolism,  sal-
vage pathway of DNA synthesis, hypoxia, angiogen-
esis, receptors (e.g. androgen receptor, gastrin releas-
ing  peptide  receptor),  prostate-specific  membrane 
antigen, prostate stem cell antigen, as well as reporter 
gene-reporter  probe  techniques  (4).      While  much 
more work needs to be done for deciphering the exact 
comparative utility of these tracers in specific clinical 
phases of prostate cancer, it is fairly clear that PET will 
play a major role in the imaging evaluation of prostate 
cancer. 
There has been considerable interest in the po-
tential  diagnostic  utility  of  PET  with  radiolabeled 
(11C- or 18F-) choline in prostate cancer (5). The bio-
logic basis for radiolabeled choline uptake in tumors 
is  the  malignancy-induced  upregulation  of  choline 
kinase, which leads to the incorporation and trapping 
of choline in the form of phosphatidylcholine in the 
tumor cell membrane.  The investigations on radio-
labeled choline in this arena have been most intense in 
the Europe and Japan.  Recently these investigations 
have reached a perceived critical mass that consensus 
guideline articles have been published (6).   In this 
issue of Theranostics, two European groups of inves-
tigators with substantial experience with choline PET 
in the imaging evaluation of prostate cancer summa-
rize  their  findings  as  well  as  those  of  others  in  the 
initial  diagnosis  and  staging  of  prostate  cancer  and 
also in men with biochemical recurrence of prostate 
cancer (7, 8).  Based on these summaries, it is expected 
that choline PET will, at least initially, play a signifi-
cant role in the imaging evaluation of men with bio-
chemical failure after definitive treatment for primary 
prostate cancer.  Exciting work remains ahead to de-
termine the exact role of choline and other promising 
PET radiotracers in prostate cancer. 
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